Details of the Drug Combination

General Information of Drug Combination (ID: DCVHR6B)

Drug Combination Name
Dasatinib Sorafenib
Indication
Disease Entry Status REF
Large cell lung carcinoma Investigative [1]
Component Drugs Dasatinib   DMJV2EK Sorafenib   DMS8IFC
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: NCI-H460
Zero Interaction Potency (ZIP) Score: 4.61
Bliss Independence Score: 6.87
Loewe Additivity Score: 5.67
LHighest Single Agent (HSA) Score: 9.65

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Dasatinib
Disease Entry ICD 11 Status REF
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive N.A. Approved [2]
Brain disease 8C70-8E61 Approved [2]
Central nervous system disease 8A04-8D87 Approved [2]
Chronic myelogenous leukaemia 2A20.0 Approved [3]
Chronic myeloid leukaemia 2A20 Approved [4]
Glioblastoma 2A00 Approved [2]
Leukemia N.A. Approved [2]
Lung cancer 2C25.0 Approved [2]
Non-small-cell lung cancer 2C25.Y Approved [2]
Plasma cell myeloma 2A83.1 Approved [2]
Multiple myeloma 2A83 Phase 2 [3]
Middle East Respiratory Syndrome (MERS) 1D64 Investigative [5]
Severe acute respiratory syndrome (SARS) 1D65 Investigative [5]
Dasatinib Interacts with 5 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
LCK tyrosine protein kinase (LCK) TT860QF LCK_HUMAN Inhibitor [11]
Fyn tyrosine protein kinase (FYN) TT2B9KF FYN_HUMAN Inhibitor [11]
Fusion protein Bcr-Abl (Bcr-Abl) TTS7G69 BCR_HUMAN-ABL1_HUMAN Inhibitor [11]
Proto-oncogene c-Src (SRC) TT6PKBN SRC_HUMAN Inhibitor [11]
HUMAN fusion protein Bcr-Abl (Bcr-Abl) TTE63HY BCR_HUMAN/ABL1_HUMAN Inhibitor [5]
------------------------------------------------------------------------------------
Dasatinib Interacts with 4 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [12]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [13]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [14]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [14]
------------------------------------------------------------------------------------
Dasatinib Interacts with 4 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [15]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Metabolism [15]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [15]
Dimethylaniline oxidase 3 (FMO3) DEP76YL FMO3_HUMAN Metabolism [16]
------------------------------------------------------------------------------------
Dasatinib Interacts with 453 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Tyrosine-protein kinase Fyn (FYN) OTLSLVZS FYN_HUMAN Affects Binding [8]
Ectonucleotide pyrophosphatase/phosphodiesterase family member 3 (ENPP3) OTB6YLFT ENPP3_HUMAN Decreases Expression [8]
Tyrosine-protein kinase HCK (HCK) OTRL6OSI HCK_HUMAN Decreases Phosphorylation [8]
CD63 antigen (CD63) OT2UGZA9 CD63_HUMAN Decreases Expression [8]
Tyrosine-protein kinase Fgr (FGR) OTCUYU9F FGR_HUMAN Affects Binding [8]
Heat shock cognate 71 kDa protein (HSPA8) OTJI2RCI HSP7C_HUMAN Affects Binding [8]
Aminopeptidase N (ANPEP) OTP3WYFD AMPN_HUMAN Decreases Expression [8]
Tyrosine-protein kinase CSK (CSK) OTP03OD0 CSK_HUMAN Affects Binding [8]
Tyrosine-protein kinase Tec (TEC) OTU6QJAJ TEC_HUMAN Affects Binding [8]
Tyrosine-protein kinase FRK (FRK) OTEKV1SC FRK_HUMAN Affects Binding [8]
Ephrin type-A receptor 5 (EPHA5) OTAM0CVX EPHA5_HUMAN Affects Binding [8]
Ephrin type-B receptor 4 (EPHB4) OTKLPVXJ EPHB4_HUMAN Affects Binding [8]
Sialomucin core protein 24 (CD164) OTZ7FIU8 MUC24_HUMAN Decreases Expression [8]
Amidophosphoribosyltransferase (PPAT) OTXK12ZB PUR1_HUMAN Affects Binding [8]
Mitogen-activated protein kinase 14 (MAPK14) OT5TCO3O MK14_HUMAN Affects Binding [8]
Mitogen-activated protein kinase kinase kinase 20 (MAP3K20) OT0ALMEG M3K20_HUMAN Affects Binding [8]
ATP-dependent RNA helicase DDX39A (DDX39A) OT0Z6E1K DX39A_HUMAN Decreases Expression [9]
Cell division cycle 7-related protein kinase (CDC7) OT5133XY CDC7_HUMAN Decreases Expression [9]
Serine/threonine-protein kinase PLK4 (PLK4) OTV8KZDZ PLK4_HUMAN Decreases Expression [9]
Nuclear envelope integral membrane protein 1 (NEMP1) OTWN3S47 NEMP1_HUMAN Decreases Expression [9]
Kinetochore protein NDC80 homolog (NDC80) OTS7D306 NDC80_HUMAN Decreases Expression [9]
Aurora kinase A (AURKA) OTMX0HYT AURKA_HUMAN Decreases Expression [9]
DNA-directed RNA polymerase III subunit RPC7 (POLR3G) OTU3TGQ9 RPC7_HUMAN Decreases Expression [9]
Fanconi anemia group A protein (FANCA) OTPEFJD4 FANCA_HUMAN Decreases Expression [9]
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Decreases Expression [9]
Monocarboxylate transporter 7 (SLC16A6) OT7BIIZX MOT7_HUMAN Decreases Expression [9]
ATP-binding cassette sub-family C member 3 (ABCC3) OTC3IJV4 MRP3_HUMAN Increases Expression [9]
Protein sprouty homolog 2 (SPRY2) OTH0CRCZ SPY2_HUMAN Decreases Expression [9]
Protein regulator of cytokinesis 1 (PRC1) OTHD0XS0 PRC1_HUMAN Decreases Expression [9]
Mitotic checkpoint serine/threonine-protein kinase BUB1 (BUB1) OT80DZMT BUB1_HUMAN Decreases Expression [9]
EGF-like repeat and discoidin I-like domain-containing protein 3 (EDIL3) OTDVVNS0 EDIL3_HUMAN Increases Expression [9]
NUAK family SNF1-like kinase 1 (NUAK1) OTLLHJJQ NUAK1_HUMAN Increases Expression [9]
Neuropilin-2 (NRP2) OTZL256E NRP2_HUMAN Increases Expression [9]
Mitotic checkpoint serine/threonine-protein kinase BUB1 beta (BUB1B) OT8KME51 BUB1B_HUMAN Decreases Expression [9]
Tetraspanin-2 (TSPAN2) OTTDPQF1 TSN2_HUMAN Increases Expression [9]
Leupaxin (LPXN) OTUNV3CK LPXN_HUMAN Decreases Expression [9]
Hyaluronan mediated motility receptor (HMMR) OT4M0JTZ HMMR_HUMAN Decreases Expression [9]
DNA polymerase theta (POLQ) OTBHK0E6 DPOLQ_HUMAN Decreases Expression [9]
Cell division control protein 45 homolog (CDC45) OT6NNLOD CDC45_HUMAN Decreases Expression [9]
Glypican-4 (GPC4) OTUJ14DW GPC4_HUMAN Increases Expression [9]
Serpin B7 (SERPINB7) OTZ95LR2 SPB7_HUMAN Decreases Expression [9]
Transient receptor potential cation channel subfamily A member 1 (TRPA1) OTRDIR5M TRPA1_HUMAN Decreases Expression [9]
Ribonuclease H2 subunit A (RNASEH2A) OT8G3G7K RNH2A_HUMAN Decreases Expression [9]
Short-chain dehydrogenase/reductase 3 (DHRS3) OTSK1DTP DHRS3_HUMAN Increases Expression [9]
Dickkopf-related protein 1 (DKK1) OTRDLUSP DKK1_HUMAN Decreases Expression [9]
Centrosomal protein of 152 kDa (CEP152) OTOKZR9B CE152_HUMAN Decreases Expression [9]
Potassium channel subfamily K member 2 (KCNK2) OTWBT8MG KCNK2_HUMAN Decreases Expression [9]
Chromosome-associated kinesin KIF4A (KIF4A) OT3UWL7D KIF4A_HUMAN Decreases Expression [9]
Structural maintenance of chromosomes protein 2 (SMC2) OT5S0DV4 SMC2_HUMAN Decreases Expression [9]
Phospholipid-transporting ATPase ABCA1 (ABCA1) OT94G6BQ ABCA1_HUMAN Increases Expression [9]
Reversion-inducing cysteine-rich protein with Kazal motifs (RECK) OT9QIHEQ RECK_HUMAN Increases Expression [9]
Securin (PTTG1) OTIMYS4W PTTG1_HUMAN Decreases Expression [9]
Histone-lysine N-methyltransferase NSD2 (NSD2) OTQ6SW4R NSD2_HUMAN Decreases Expression [9]
Aldehyde dehydrogenase 1A1 (ALDH1A1) OTCUWZKB AL1A1_HUMAN Increases Expression [9]
Dihydrofolate reductase (DHFR) OT3DVIGM DYR_HUMAN Decreases Expression [9]
Complement C1r subcomponent (C1R) OTA0ZNIU C1R_HUMAN Increases Expression [9]
Urokinase-type plasminogen activator (PLAU) OTX0QGKK UROK_HUMAN Decreases Expression [9]
Alpha-2-macroglobulin (A2M) OTFTX90K A2MG_HUMAN Increases Expression [9]
Insulin-like growth factor II (IGF2) OTJ4O6MW IGF2_HUMAN Increases Expression [9]
Collagen alpha-1(III) chain (COL3A1) OTT1EMLM CO3A1_HUMAN Increases Expression [9]
Collagen alpha-1(IV) chain (COL4A1) OTL6D1YE CO4A1_HUMAN Increases Expression [9]
Alpha-crystallin B chain (CRYAB) OTY4JGYU CRYAB_HUMAN Increases Expression [9]
Interstitial collagenase (MMP1) OTI4I2V1 MMP1_HUMAN Decreases Expression [9]
Thymidine kinase, cytosolic (TK1) OTY5JFM1 KITH_HUMAN Decreases Expression [9]
Aldehyde dehydrogenase, mitochondrial (ALDH2) OTKJ9I3N ALDH2_HUMAN Increases Expression [9]
Plasminogen activator inhibitor 2 (SERPINB2) OT72QLZB PAI2_HUMAN Decreases Expression [9]
Interleukin-6 (IL6) OTUOSCCU IL6_HUMAN Increases Expression [9]
Cyclin-dependent kinase 1 (CDK1) OTW1SC2N CDK1_HUMAN Decreases Expression [9]
Integrin alpha-V (ITGAV) OTAM7JTR ITAV_HUMAN Increases Expression [9]
Epoxide hydrolase 1 (EPHX1) OTBKWQER HYEP_HUMAN Increases Expression [9]
Neurofilament medium polypeptide (NEFM) OT8VCBNF NFM_HUMAN Decreases Expression [9]
Laminin subunit beta-1 (LAMB1) OT6J9LJR LAMB1_HUMAN Increases Expression [9]
Asparagine synthetase (ASNS) OT8R922G ASNS_HUMAN Increases Expression [9]
Matrix Gla protein (MGP) OTZWU3FU MGP_HUMAN Increases Expression [9]
Collagen alpha-2(IV) chain (COL4A2) OTJK1LKN CO4A2_HUMAN Increases Expression [9]
Platelet-derived growth factor receptor beta (PDGFRB) OTYSNK9Q PGFRB_HUMAN Increases Expression [9]
Complement C1s subcomponent (C1S) OTCIZU2A C1S_HUMAN Increases Expression [9]
DNA polymerase alpha catalytic subunit (POLA1) OT1WXFVY DPOLA_HUMAN Decreases Expression [9]
Histone H2A.Z (H2AZ1) OT3KJJNQ H2AZ_HUMAN Decreases Expression [9]
Myb-related protein A (MYBL1) OTBJMC2P MYBA_HUMAN Decreases Expression [9]
Myb-related protein B (MYBL2) OTZ3JX8Q MYBB_HUMAN Decreases Expression [9]
Histone H1.4 (H1-4) OTQ450A3 H14_HUMAN Decreases Expression [9]
Clusterin (CLU) OTQGG0JM CLUS_HUMAN Increases Expression [9]
DNA topoisomerase 2-alpha (TOP2A) OT6LPS08 TOP2A_HUMAN Decreases Expression [9]
Fibroblast growth factor 5 (FGF5) OTQXGHBY FGF5_HUMAN Decreases Expression [9]
Collagen alpha-1(XI) chain (COL11A1) OTB0DRMS COBA1_HUMAN Increases Expression [9]
Elastin (ELN) OTFSO7PG ELN_HUMAN Increases Expression [9]
Aggrecan core protein (ACAN) OTUOCW8K PGCA_HUMAN Increases Expression [9]
Histone H1.5 (H1-5) OTAN7RD9 H15_HUMAN Decreases Expression [9]
Stathmin (STMN1) OTDJ4RV0 STMN1_HUMAN Decreases Expression [9]
Lamin-B1 (LMNB1) OT100T3P LMNB1_HUMAN Decreases Expression [9]
Biglycan (BGN) OT3AV6IF PGS1_HUMAN Increases Expression [9]
Ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1) OT3MPPYX ENPP1_HUMAN Decreases Expression [9]
Liver carboxylesterase 1 (CES1) OT9L0LR8 EST1_HUMAN Increases Expression [9]
Integrin alpha-6 (ITGA6) OT3FA39C ITA6_HUMAN Decreases Expression [9]
Ribonucleoside-diphosphate reductase large subunit (RRM1) OTXGQOR9 RIR1_HUMAN Decreases Expression [9]
Insulin-like growth factor-binding protein 5 (IGFBP5) OTRE5V0C IBP5_HUMAN Increases Expression [9]
Cyclin-dependent kinase 2 (CDK2) OTB5DYYZ CDK2_HUMAN Decreases Expression [9]
Pentraxin-related protein PTX3 (PTX3) OTPXHRKU PTX3_HUMAN Decreases Expression [9]
High mobility group protein B2 (HMGB2) OTGEGAOK HMGB2_HUMAN Decreases Expression [9]
Cardiac phospholamban (PLN) OTT3RRJN PPLA_HUMAN Increases Expression [9]
G0/G1 switch protein 2 (G0S2) OT8FL49L G0S2_HUMAN Decreases Expression [9]
Dipeptidyl peptidase 4 (DPP4) OT16MVL9 DPP4_HUMAN Increases Expression [9]
Leiomodin-1 (LMOD1) OTZ2MEMG LMOD1_HUMAN Increases Expression [9]
M-phase inducer phosphatase 1 (CDC25A) OTSLKKCO MPIP1_HUMAN Decreases Expression [9]
M-phase inducer phosphatase 3 (CDC25C) OTPQI71S MPIP3_HUMAN Decreases Expression [9]
Ribonucleoside-diphosphate reductase subunit M2 (RRM2) OTOB6J6R RIR2_HUMAN Decreases Expression [9]
Fibroblast growth factor 9 (FGF9) OT2SKDGM FGF9_HUMAN Increases Expression [9]
Sodium- and chloride-dependent taurine transporter (SLC6A6) OT67U7G3 SC6A6_HUMAN Increases Expression [9]
Cyclin-dependent kinases regulatory subunit 2 (CKS2) OTPTMHIV CKS2_HUMAN Decreases Expression [9]
Histone H2B type 1-B (H2BC3) OT1BLFJO H2B1B_HUMAN Decreases Expression [9]
Dual specificity protein kinase TTK (TTK) OTBY1Z5H TTK_HUMAN Decreases Expression [9]
DNA replication licensing factor MCM7 (MCM7) OT6FXC6K MCM7_HUMAN Decreases Expression [9]
Syndecan-2 (SDC2) OTEEHY1D SDC2_HUMAN Increases Expression [9]
Replication factor C subunit 4 (RFC4) OTWALD2R RFC4_HUMAN Decreases Expression [9]
Replication factor C subunit 2 (RFC2) OTJ9N6BD RFC2_HUMAN Decreases Expression [9]
Thrombospondin-2 (THBS2) OTXET551 TSP2_HUMAN Increases Expression [9]
Myosin-10 (MYH10) OTXN2WXS MYH10_HUMAN Increases Expression [9]
Myosin-11 (MYH11) OTVNVWY3 MYH11_HUMAN Increases Expression [9]
Chitinase-3-like protein 1 (CHI3L1) OT2Z7VJH CH3L1_HUMAN Increases Expression [9]
Breast cancer type 1 susceptibility protein (BRCA1) OT5BN6VH BRCA1_HUMAN Decreases Expression [9]
Flap endonuclease 1 (FEN1) OT6QGG7O FEN1_HUMAN Decreases Expression [9]
Nicotinamide N-methyltransferase (NNMT) OTFM38GU NNMT_HUMAN Increases Expression [9]
Pre-B-cell leukemia transcription factor 1 (PBX1) OTORABGO PBX1_HUMAN Increases Expression [9]
Replication factor C subunit 5 (RFC5) OTAD79RT RFC5_HUMAN Decreases Expression [9]
Replication factor C subunit 3 (RFC3) OT1MS7AO RFC3_HUMAN Decreases Expression [9]
5-hydroxytryptamine receptor 2B (HTR2B) OTM1AD9J 5HT2B_HUMAN Increases Expression [9]
Lamina-associated polypeptide 2, isoform alpha (TMPO) OTL68EL4 LAP2A_HUMAN Decreases Expression [9]
Aldo-keto reductase family 1 member C3 (AKR1C3) OTU2SXBA AK1C3_HUMAN Increases Expression [9]
Condensin-2 complex subunit D3 (NCAPD3) OTOZY2UL CNDD3_HUMAN Decreases Expression [9]
Neutral amino acid transporter A (SLC1A4) OTVODHAE SATT_HUMAN Increases Expression [9]
Cell surface glycoprotein MUC18 (MCAM) OTT8XKGE MUC18_HUMAN Increases Expression [9]
DNA mismatch repair protein Msh2 (MSH2) OT10H1AB MSH2_HUMAN Decreases Expression [9]
Proliferation marker protein Ki-67 (MKI67) OTA8N1QI KI67_HUMAN Decreases Expression [9]
Glutathione S-transferase Mu 5 (GSTM5) OTMMBFY8 GSTM5_HUMAN Increases Expression [9]
Histone H3-like centromeric protein A (CENPA) OT0NEJ4X CENPA_HUMAN Decreases Expression [9]
Centromere protein F (CENPF) OT7AG0SW CENPF_HUMAN Decreases Expression [9]
DNA primase small subunit (PRIM1) OTWWP8Y6 PRI1_HUMAN Decreases Expression [9]
DNA primase large subunit (PRIM2) OTGT0KTF PRI2_HUMAN Decreases Expression [9]
Thrombospondin-3 (THBS3) OTDKMUBD TSP3_HUMAN Increases Expression [9]
Regulator of G-protein signaling 4 (RGS4) OTG94HHL RGS4_HUMAN Decreases Expression [9]
Selenoprotein P (SELENOP) OT02B8IR SEPP1_HUMAN Increases Expression [9]
Kinetochore-associated protein 1 (KNTC1) OTI2OOFN KNTC1_HUMAN Decreases Expression [9]
Ras association domain-containing protein 2 (RASSF2) OT2JHDO4 RASF2_HUMAN Increases Expression [9]
DNA replication ATP-dependent helicase/nuclease DNA2 (DNA2) OT4DJFFU DNA2_HUMAN Decreases Expression [9]
Breast cancer type 2 susceptibility protein (BRCA2) OTF1XSV1 BRCA2_HUMAN Decreases Expression [9]
Lumican (LUM) OTSRC874 LUM_HUMAN Increases Expression [9]
Calponin-1 (CNN1) OTVPG39Z CNN1_HUMAN Increases Expression [9]
Importin subunit alpha-1 (KPNA2) OTU7FOE6 IMA1_HUMAN Decreases Expression [9]
Stanniocalcin-1 (STC1) OTGVVXYF STC1_HUMAN Decreases Expression [9]
High mobility group protein HMGI-C (HMGA2) OTBMBHHL HMGA2_HUMAN Decreases Expression [9]
Serine/threonine-protein kinase PLK1 (PLK1) OTRZX45T PLK1_HUMAN Decreases Expression [9]
Microfibril-associated glycoprotein 4 (MFAP4) OT5W64QY MFAP4_HUMAN Increases Expression [9]
DNA polymerase epsilon subunit 2 (POLE2) OTAC9V6L DPOE2_HUMAN Decreases Expression [9]
Cyclin-dependent kinases regulatory subunit 1 (CKS1B) OTNUPLUJ CKS1_HUMAN Decreases Expression [9]
Transforming growth factor beta-2 proprotein (TGFB2) OTC0TXEP TGFB2_HUMAN Increases Expression [9]
Actin, aortic smooth muscle (ACTA2) OTEDLG8E ACTA_HUMAN Increases Expression [9]
Actin, gamma-enteric smooth muscle (ACTG2) OTRDWUO0 ACTH_HUMAN Increases Expression [9]
Actin, alpha cardiac muscle 1 (ACTC1) OTJU04B1 ACTC_HUMAN Increases Expression [9]
Protein jagged-1 (JAG1) OT3LGT6K JAG1_HUMAN Increases Expression [9]
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) OTEUYEW6 ROR1_HUMAN Increases Expression [9]
Centromere-associated protein E (CENPE) OTQ7AP04 CENPE_HUMAN Decreases Expression [9]
Kinesin-like protein KIF23 (KIF23) OTY850JC KIF23_HUMAN Decreases Expression [9]
Histone H1.1 (H1-1) OTSS815G H11_HUMAN Decreases Expression [9]
Aldehyde oxidase (AOX1) OT2FZP6H AOXA_HUMAN Decreases Expression [9]
DNA repair protein RAD51 homolog 1 (RAD51) OTNVWGC1 RAD51_HUMAN Decreases Expression [9]
Transcription factor SOX-4 (SOX4) OTSS40SS SOX4_HUMAN Increases Expression [9]
Prolow-density lipoprotein receptor-related protein 1 (LRP1) OTHTEH4G LRP1_HUMAN Increases Expression [9]
Forkhead box protein M1 (FOXM1) OT5887KR FOXM1_HUMAN Decreases Expression [9]
Lactadherin (MFGE8) OTQKE41R MFGM_HUMAN Increases Expression [9]
EGF-containing fibulin-like extracellular matrix protein 1 (EFEMP1) OTZVUOOB FBLN3_HUMAN Increases Expression [9]
Cell division cycle protein 20 homolog (CDC20) OTCOEZRV CDC20_HUMAN Decreases Expression [9]
Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial (ECH1) OTA0UNHM ECH1_HUMAN Increases Expression [9]
MAL-like protein (MALL) OTKGZ89D MALL_HUMAN Decreases Expression [9]
Mitotic spindle assembly checkpoint protein MAD2A (MAD2L1) OTXNGZCG MD2L1_HUMAN Decreases Expression [9]
Centromere protein R (ITGB3BP) OT6Q7GR3 CENPR_HUMAN Decreases Expression [9]
Origin recognition complex subunit 1 (ORC1) OTHWU8IJ ORC1_HUMAN Decreases Expression [9]
Limbic system-associated membrane protein (LSAMP) OTYXVQX2 LSAMP_HUMAN Increases Expression [9]
Four and a half LIM domains protein 1 (FHL1) OTN535SU FHL1_HUMAN Increases Expression [9]
Voltage-dependent L-type calcium channel subunit alpha-1C (CACNA1C) OT6KFNMS CAC1C_HUMAN Increases Expression [9]
DNA polymerase alpha subunit B (POLA2) OTTWQ73N DPOA2_HUMAN Decreases Expression [9]
Fibroleukin (FGL2) OT8M3H72 FGL2_HUMAN Increases Expression [9]
cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A (PDE3A) OTKUW1WT PDE3A_HUMAN Increases Expression [9]
Semaphorin-3A (SEMA3A) OTQJSV7W SEM3A_HUMAN Decreases Expression [9]
DNA replication licensing factor MCM6 (MCM6) OTKLIAWT MCM6_HUMAN Decreases Expression [9]
Inositol 1,4,5-trisphosphate receptor type 1 (ITPR1) OTX7MWW1 ITPR1_HUMAN Increases Expression [9]
Maternal embryonic leucine zipper kinase (MELK) OTEY2UQA MELK_HUMAN Decreases Expression [9]
DNA replication complex GINS protein PSF1 (GINS1) OTVQZMMQ PSF1_HUMAN Decreases Expression [9]
Transmembrane glycoprotein NMB (GPNMB) OTB7KQKV GPNMB_HUMAN Increases Expression [9]
Condensin complex subunit 2 (NCAPH) OTXOS97C CND2_HUMAN Decreases Expression [9]
PCNA-associated factor (PCLAF) OTMVIOUU PAF15_HUMAN Decreases Expression [9]
Condensin complex subunit 1 (NCAPD2) OT8VGE2O CND1_HUMAN Decreases Expression [9]
Disks large-associated protein 5 (DLGAP5) OTWCN39U DLGP5_HUMAN Decreases Expression [9]
SCL-interrupting locus protein (STIL) OT9799VN STIL_HUMAN Decreases Expression [9]
Pachytene checkpoint protein 2 homolog (TRIP13) OTFM3TI9 PCH2_HUMAN Decreases Expression [9]
Myosin light chain kinase, smooth muscle (MYLK) OT78QB4A MYLK_HUMAN Increases Expression [9]
Histone-lysine N-methyltransferase EZH2 (EZH2) OTIEHTKW EZH2_HUMAN Decreases Expression [9]
Insulin-like growth factor-binding protein 7 (IGFBP7) OT1D416P IBP7_HUMAN Increases Expression [9]
Neuronal regeneration-related protein (NREP) OT2AZPKK NREP_HUMAN Increases Expression [9]
Prostacyclin synthase (PTGIS) OTT3RW6N PTGIS_HUMAN Increases Expression [9]
Cyclin-dependent kinase inhibitor 3 (CDKN3) OTBE3H07 CDKN3_HUMAN Decreases Expression [9]
Cytochrome P450 1B1 (CYP1B1) OTYXFLSD CP1B1_HUMAN Increases Expression [9]
Phosphoenolpyruvate carboxykinase , mitochondrial (PCK2) OTJ8LX4N PCKGM_HUMAN Increases Expression [9]
Tumor protein D53 (TPD52L1) OTSA6U0I TPD53_HUMAN Increases Expression [9]
Flap endonuclease GEN homolog 1 (GEN1) OT1XFQXF GEN_HUMAN Decreases Expression [9]
Mitochondrial 10-formyltetrahydrofolate dehydrogenase (ALDH1L2) OTCH86VF AL1L2_HUMAN Increases Expression [9]
Sushi, von Willebrand factor type A, EGF and pentraxin domain-containing protein 1 (SVEP1) OTOBICRD SVEP1_HUMAN Increases Expression [9]
Borealin (CDCA8) OT17D55D BOREA_HUMAN Decreases Expression [9]
Protein LBH (LBH) OT87AT1X LBH_HUMAN Increases Expression [9]
Shugoshin 2 (SGO2) OTNGJDS8 SGO2_HUMAN Decreases Expression [9]
Centromere protein W (CENPW) OTZL05QN CENPW_HUMAN Decreases Expression [9]
Shugoshin 1 (SGO1) OTIP6IRN SGO1_HUMAN Decreases Expression [9]
Probable E3 ubiquitin-protein ligase HERC4 (HERC4) OTU4DSDE HERC4_HUMAN Decreases Expression [9]
Testis-expressed protein 30 (TEX30) OT87WEPQ TEX30_HUMAN Decreases Expression [9]
DEP domain-containing protein 1A (DEPDC1) OT0JWE1B DEP1A_HUMAN Decreases Expression [9]
Tensin-3 (TNS3) OTPG2D8Z TENS3_HUMAN Increases Expression [9]
Cell division cycle-associated protein 2 (CDCA2) OTX8UF9J CDCA2_HUMAN Decreases Expression [9]
Protein FAM72D (FAM72D) OTCQVOXB FA72D_HUMAN Decreases Expression [9]
Repulsive guidance molecule B (RGMB) OT2DROYU RGMB_HUMAN Decreases Expression [9]
STEAP family member 1B (STEAP1B) OTZJDFWK STEAL_HUMAN Decreases Expression [9]
Mis18-binding protein 1 (MIS18BP1) OT41T0FB M18BP_HUMAN Decreases Expression [9]
Mitochondrial fission regulator 2 (MTFR2) OTLOR68D MTFR2_HUMAN Decreases Expression [9]
Rho GTPase-activating protein 11A (ARHGAP11A) OTVQCFVP RHGBA_HUMAN Decreases Expression [9]
E3 ubiquitin-protein ligase RFWD3 (RFWD3) OTDUULBQ RFWD3_HUMAN Decreases Expression [9]
Podocan-like protein 1 (PODNL1) OTL72ES9 PONL1_HUMAN Increases Expression [9]
Protein aurora borealis (BORA) OTV2ZPKP BORA_HUMAN Decreases Expression [9]
Neutral cholesterol ester hydrolase 1 (NCEH1) OTZ66CKX NCEH1_HUMAN Decreases Expression [9]
Fidgetin-like protein 1 (FIGNL1) OTKII63K FIGL1_HUMAN Decreases Expression [9]
ATPase family AAA domain-containing protein 2 (ATAD2) OT8MCRNY ATAD2_HUMAN Decreases Expression [9]
Serine protease FAM111B (FAM111B) OT9IQ9NV F111B_HUMAN Decreases Expression [9]
Protein FAM180A (FAM180A) OTKQ7XUG F180A_HUMAN Decreases Expression [9]
Golgi-associated kinase 1B (GASK1B) OT2HPHEI GAK1B_HUMAN Increases Expression [9]
Plexin domain-containing protein 2 (PLXDC2) OTS1FUV6 PXDC2_HUMAN Increases Expression [9]
ALK and LTK ligand 1 (ALKAL1) OTZGAZ79 ALKL1_HUMAN Increases Expression [9]
Protein MMS22-like (MMS22L) OTJI0HM9 MMS22_HUMAN Decreases Expression [9]
Centrosomal protein of 128 kDa (CEP128) OT922YCJ CE128_HUMAN Decreases Expression [9]
DNA-binding protein RFX8 (RFX8) OT27SFGQ RFX8_HUMAN Decreases Expression [9]
Centromere protein U (CENPU) OTQ4TZRS CENPU_HUMAN Decreases Expression [9]
Protein MCM10 homolog (MCM10) OTV0O3JN MCM10_HUMAN Decreases Expression [9]
Treslin (TICRR) OT2HKWOC TICRR_HUMAN Decreases Expression [9]
MAM domain-containing protein 2 (MAMDC2) OT4GICNY MAMC2_HUMAN Increases Expression [9]
LisH domain-containing protein ARMC9 (ARMC9) OT0MZER2 ARMC9_HUMAN Increases Expression [9]
Rho GTPase-activating protein 22 (ARHGAP22) OTXUQEFL RHG22_HUMAN Decreases Expression [9]
Podocan (PODN) OTV3P7P5 PODN_HUMAN Increases Expression [9]
Schlafen family member 11 (SLFN11) OTJWFPMY SLN11_HUMAN Decreases Expression [9]
Amphoterin-induced protein 2 (AMIGO2) OTPAIT1O AMGO2_HUMAN Increases Expression [9]
Alpha-protein kinase 2 (ALPK2) OTWZZDQ9 ALPK2_HUMAN Increases Expression [9]
Myopalladin (MYPN) OTHTOFDU MYPN_HUMAN Decreases Expression [9]
E3 ubiquitin-protein ligase MARCHF3 (MARCHF3) OT89V4N5 MARH3_HUMAN Decreases Expression [9]
Ras GTPase-activating-like protein IQGAP3 (IQGAP3) OT4RZV2M IQGA3_HUMAN Decreases Expression [9]
Condensin-2 complex subunit G2 (NCAPG2) OTZYENKO CNDG2_HUMAN Decreases Expression [9]
GAS2-like protein 3 (GAS2L3) OTWPVI29 GA2L3_HUMAN Decreases Expression [9]
Histone H2A type 2-B (H2AC21) OTH7W2NJ H2A2B_HUMAN Decreases Expression [9]
Pleckstrin homology domain-containing family H member 2 (PLEKHH2) OT3TK3NN PKHH2_HUMAN Increases Expression [9]
Extracellular sulfatase Sulf-2 (SULF2) OTIXMUVL SULF2_HUMAN Increases Expression [9]
Extracellular sulfatase Sulf-1 (SULF1) OTJCNCO0 SULF1_HUMAN Increases Expression [9]
CD302 antigen (CD302) OTX580VU CD302_HUMAN Increases Expression [9]
Spindle and kinetochore-associated protein 3 (SKA3) OTLHEVJD SKA3_HUMAN Decreases Expression [9]
DNA damage-induced apoptosis suppressor protein (DDIAS) OTTGG2PM DDIAS_HUMAN Decreases Expression [9]
Cytoskeleton-associated protein 2-like (CKAP2L) OT4T73GG CKP2L_HUMAN Decreases Expression [9]
Fanconi anemia group M protein (FANCM) OTNJG99Z FANCM_HUMAN Decreases Expression [9]
Lung adenoma susceptibility protein 2 (C18ORF54) OT4WJKTF LAS2_HUMAN Decreases Expression [9]
Abnormal spindle-like microcephaly-associated protein (ASPM) OTKXQMNA ASPM_HUMAN Decreases Expression [9]
Retinol dehydrogenase 10 (RDH10) OTL9FSGF RDH10_HUMAN Increases Expression [9]
Centromere protein L (CENPL) OT7P006B CENPL_HUMAN Decreases Expression [9]
Rho GTPase-activating protein 18 (ARHGAP18) OTYMJP6H RHG18_HUMAN Decreases Expression [9]
T-complex protein 11-like protein 2 (TCP11L2) OTTIZO7B T11L2_HUMAN Increases Expression [9]
Aminopeptidase O (AOPEP) OT0MMANL AMPO_HUMAN Increases Expression [9]
Junction-mediating and -regulatory protein (JMY) OTH5FFVK JMY_HUMAN Increases Expression [9]
Holliday junction recognition protein (HJURP) OTWMV16B HJURP_HUMAN Decreases Expression [9]
SHC SH2 domain-binding protein 1 (SHCBP1) OT3A21CM SHCBP_HUMAN Decreases Expression [9]
MAM domain-containing glycosylphosphatidylinositol anchor protein 1 (MDGA1) OTVXEF85 MDGA1_HUMAN Increases Expression [9]
(Lyso)-N-acylphosphatidylethanolamine lipase (ABHD4) OTQK3M9X ABHD4_HUMAN Increases Expression [9]
DEP domain-containing mTOR-interacting protein (DEPTOR) OTCBP1BT DPTOR_HUMAN Increases Expression [9]
Protein CIP2A (CIP2A) OTVS2GXA CIP2A_HUMAN Decreases Expression [9]
Sodium-dependent phosphate transporter 1 (SLC20A1) OTC3D894 S20A1_HUMAN Decreases Expression [9]
DEP domain-containing protein 1B (DEPDC1B) OTMVFOT1 DEP1B_HUMAN Decreases Expression [9]
Basic helix-loop-helix ARNT-like protein 2 (BMAL2) OTIBDGQC BMAL2_HUMAN Decreases Expression [9]
Centromere protein I (CENPI) OTWRIMZ3 CENPI_HUMAN Decreases Expression [9]
Serine protease HTRA1 (HTRA1) OTR8ACBF HTRA1_HUMAN Increases Expression [9]
Hyaluronan synthase 2 (HAS2) OTTD3PAL HYAS2_HUMAN Decreases Expression [9]
Neogenin (NEO1) OTGJ1997 NEO1_HUMAN Increases Expression [9]
Histone H2B type 1-H (H2BC9) OTQ9XX72 H2B1H_HUMAN Decreases Expression [9]
F-box only protein 32 (FBXO32) OTUE978R FBX32_HUMAN Increases Expression [9]
Tumor protein p53-inducible nuclear protein 1 (TP53INP1) OT2363Z9 T53I1_HUMAN Increases Expression [9]
Transcription factor E2F7 (E2F7) OTWW358N E2F7_HUMAN Decreases Expression [9]
Spindle and kinetochore-associated protein 1 (SKA1) OTDYJ12A SKA1_HUMAN Decreases Expression [9]
Mdm2-binding protein (MTBP) OTWLCW9C MTBP_HUMAN Decreases Expression [9]
Sororin (CDCA5) OTZLCQ5U CDCA5_HUMAN Decreases Expression [9]
Aurora kinase B (AURKB) OTIY4VHU AURKB_HUMAN Decreases Expression [9]
Serine/threonine-protein kinase greatwall (MASTL) OTQ7YKK5 GWL_HUMAN Decreases Expression [9]
Centromere protein N (CENPN) OTRO7XPD CENPN_HUMAN Decreases Expression [9]
Proline-rich protein 11 (PRR11) OT2JJ08Z PRR11_HUMAN Decreases Expression [9]
Lymphokine-activated killer T-cell-originated protein kinase (PBK) OT5Z27TW TOPK_HUMAN Decreases Expression [9]
Leucine-rich repeat protein 1 (LRR1) OTSWDXVY LLR1_HUMAN Decreases Expression [9]
Protein-L-isoaspartate O-methyltransferase domain-containing protein 1 (PCMTD1) OT5TS6P7 PCMD1_HUMAN Increases Expression [9]
Discoidin, CUB and LCCL domain-containing protein 2 (DCBLD2) OTB71I02 DCBD2_HUMAN Decreases Expression [9]
Kinesin-like protein KIF20B (KIF20B) OTS68AHH KI20B_HUMAN Decreases Expression [9]
ATPase family AAA domain-containing protein 5 (ATAD5) OTI8ABKF ATAD5_HUMAN Decreases Expression [9]
Hemicentin-1 (HMCN1) OTLZAS0P HMCN1_HUMAN Increases Expression [9]
Hyaluronan and proteoglycan link protein 3 (HAPLN3) OTB853Z1 HPLN3_HUMAN Increases Expression [9]
Proheparin-binding EGF-like growth factor (HBEGF) OTLU00JS HBEGF_HUMAN Decreases Expression [9]
Cell division cycle-associated protein 3 (CDCA3) OTUI8QK3 CDCA3_HUMAN Decreases Expression [9]
Kinesin-like protein KIF2C (KIF2C) OTJ8G3NP KIF2C_HUMAN Decreases Expression [9]
Cell division control protein 6 homolog (CDC6) OTX93FE7 CDC6_HUMAN Decreases Expression [9]
Endothelial PAS domain-containing protein 1 (EPAS1) OTRE3O8U EPAS1_HUMAN Increases Expression [9]
Histone H2B type 1-M (H2BC14) OTSDZZZY H2B1M_HUMAN Decreases Expression [9]
Condensin complex subunit 3 (NCAPG) OT1AI9EO CND3_HUMAN Decreases Expression [9]
Mitochondrial genome maintenance exonuclease 1 (MGME1) OTC5LPXX MGME1_HUMAN Decreases Expression [9]
Synaptotagmin-15 (SYT15) OT7Q088G SYT15_HUMAN Increases Expression [9]
Hephaestin (HEPH) OTZ2F15Z HEPH_HUMAN Increases Expression [9]
DNA replication complex GINS protein SLD5 (GINS4) OTCVOO3S SLD5_HUMAN Decreases Expression [9]
Centromere protein K (CENPK) OTKPUF8K CENPK_HUMAN Decreases Expression [9]
Protein PIMREG (PIMREG) OTKC8T3E PIMRE_HUMAN Decreases Expression [9]
Nucleoporin NDC1 (NDC1) OTF2GQC1 NDC1_HUMAN Decreases Expression [9]
Centromere protein O (CENPO) OTXAH83Y CENPO_HUMAN Decreases Expression [9]
Glutathione-specific gamma-glutamylcyclotransferase 1 (CHAC1) OTJGE772 CHAC1_HUMAN Increases Expression [9]
TIMELESS-interacting protein (TIPIN) OT9PZHXV TIPIN_HUMAN Decreases Expression [9]
Kinesin-like protein KIFC1 (KIFC1) OTNQDS00 KIFC1_HUMAN Decreases Expression [9]
Meiotic nuclear division protein 1 homolog (MND1) OTS87F3H MND1_HUMAN Decreases Expression [9]
Nucleolar and spindle-associated protein 1 (NUSAP1) OT85HIJ5 NUSAP_HUMAN Decreases Expression [9]
Fanconi anemia group D2 protein (FANCD2) OTVEB5LF FACD2_HUMAN Decreases Expression [9]
Transmembrane 6 superfamily member 1 (TM6SF1) OTQR4I2N TM6S1_HUMAN Increases Expression [9]
Cysteine-rich secretory protein LCCL domain-containing 2 (CRISPLD2) OTVSFHTL CRLD2_HUMAN Increases Expression [9]
Rac GTPase-activating protein 1 (RACGAP1) OTQE8IEH RGAP1_HUMAN Decreases Expression [9]
Centromere protein H (CENPH) OTPOO9LK CENPH_HUMAN Decreases Expression [9]
Kinetochore-associated protein DSN1 homolog (DSN1) OTHROI0H DSN1_HUMAN Decreases Expression [9]
Uncharacterized protein C1orf198 (C1ORF198) OTK3L4G7 CA198_HUMAN Increases Expression [9]
Golgi-associated plant pathogenesis-related protein 1 (GLIPR2) OTFTH6ZY GAPR1_HUMAN Increases Expression [9]
Very long chain fatty acid elongase 6 (ELOVL6) OTB26UJJ ELOV6_HUMAN Decreases Expression [9]
Anthrax toxin receptor 1 (ANTXR1) OT5W1GPC ANTR1_HUMAN Increases Expression [9]
Gremlin-2 (GREM2) OTE91EWT GREM2_HUMAN Increases Expression [9]
Metal transporter CNNM2 (CNNM2) OTZHO8WU CNNM2_HUMAN Increases Expression [9]
Protein ECT2 (ECT2) OTQDUCT6 ECT2_HUMAN Decreases Expression [9]
Claspin (CLSPN) OTZZXNDK CLSPN_HUMAN Decreases Expression [9]
Mineralization regulator ANKH (ANKH) OTCN25R5 ANKH_HUMAN Increases Expression [9]
Ribonucleoprotein PTB-binding 2 (RAVER2) OT0MDL7K RAVR2_HUMAN Increases Expression [9]
Neurexin-3-beta (NRXN3) OTJ0I7HJ NRX3B_HUMAN Increases Expression [9]
Solute carrier family 40 member 1 (SLC40A1) OT8RV2VY S40A1_HUMAN Increases Expression [9]
Anillin (ANLN) OTXJY54C ANLN_HUMAN Decreases Expression [9]
Phospholipid scramblase 4 (PLSCR4) OT2AMYLY PLS4_HUMAN Increases Expression [9]
Lymphoid-specific helicase (HELLS) OTVVV668 HELLS_HUMAN Decreases Expression [9]
FIGNL1-interacting regulator of recombination and mitosis (FIRRM) OTALLHT1 FIRRM_HUMAN Decreases Expression [9]
Protein diaphanous homolog 3 (DIAPH3) OTPOT23F DIAP3_HUMAN Decreases Expression [9]
Structural maintenance of chromosomes protein 4 (SMC4) OTEJE6AG SMC4_HUMAN Decreases Expression [9]
Protein DEPP1 (DEPP1) OTB36PHJ DEPP1_HUMAN Increases Expression [9]
Tyrosyl-DNA phosphodiesterase 1 (TDP1) OTYINMBR TYDP1_HUMAN Decreases Expression [9]
Fanconi anemia group I protein (FANCI) OTW8E3SC FANCI_HUMAN Decreases Expression [9]
Histone chaperone ASF1B (ASF1B) OTKXX12I ASF1B_HUMAN Decreases Expression [9]
PCNA-interacting partner (PARPBP) OTPZDGW7 PARI_HUMAN Decreases Expression [9]
DNA damage-inducible transcript 4 protein (DDIT4) OTHY8SY4 DDIT4_HUMAN Increases Expression [9]
Dapper homolog 1 (DACT1) OT19Z704 DACT1_HUMAN Increases Expression [9]
Protein Mis18-alpha (MIS18A) OTD80K5X MS18A_HUMAN Decreases Expression [9]
Denticleless protein homolog (DTL) OTC29RYE DTL_HUMAN Decreases Expression [9]
Programmed cell death 1 ligand 1 (CD274) OTJ0VFDL PD1L1_HUMAN Decreases Expression [9]
LIM and cysteine-rich domains protein 1 (LMCD1) OT3AWE8O LMCD1_HUMAN Increases Expression [9]
Calcium-binding and coiled-coil domain-containing protein 1 (CALCOCO1) OT1PAIN0 CACO1_HUMAN Increases Expression [9]
Homologous-pairing protein 2 homolog (PSMC3IP) OT9UB5UO HOP2_HUMAN Decreases Expression [9]
Fibulin-5 (FBLN5) OTLVNZ8U FBLN5_HUMAN Increases Expression [9]
DNA dC->dU-editing enzyme APOBEC-3B (APOBEC3B) OTHLNI51 ABC3B_HUMAN Decreases Expression [9]
STEAP1 protein (STEAP1) OTJMW5R9 STEA1_HUMAN Decreases Expression [9]
Carboxypeptidase A4 (CPA4) OT66MP0F CBPA4_HUMAN Decreases Expression [9]
DNA helicase MCM8 (MCM8) OTC93H3S MCM8_HUMAN Decreases Expression [9]
F-box only protein 5 (FBXO5) OTTR957W FBX5_HUMAN Decreases Expression [9]
Angiopoietin-related protein 2 (ANGPTL2) OTB6JG41 ANGL2_HUMAN Increases Expression [9]
Integrin alpha-11 (ITGA11) OTBWSRA1 ITA11_HUMAN Increases Expression [9]
Protein HEG homolog 1 (HEG1) OT3CUXA7 HEG1_HUMAN Increases Expression [9]
Targeting protein for Xklp2 (TPX2) OTWLJYH0 TPX2_HUMAN Decreases Expression [9]
Synaptopodin-2 (SYNPO2) OTC3U0YH SYNP2_HUMAN Increases Expression [9]
A disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS5) OT953SV2 ATS5_HUMAN Increases Expression [9]
Protein timeless homolog (TIMELESS) OTD8DCBJ TIM_HUMAN Decreases Expression [9]
LIM and calponin homology domains-containing protein 1 (LIMCH1) OTYPC4XA LIMC1_HUMAN Increases Expression [9]
Exonuclease 1 (EXO1) OTI87RS5 EXO1_HUMAN Decreases Expression [9]
Protein phosphatase 1 regulatory subunit 3C (PPP1R3C) OTEU05TX PPR3C_HUMAN Increases Expression [9]
Transcription factor 19 (TCF19) OT7NKLF9 TCF19_HUMAN Decreases Expression [9]
DNA replication complex GINS protein PSF2 (GINS2) OT974IYI PSF2_HUMAN Decreases Expression [9]
Serine/threonine-protein kinase 38-like (STK38L) OTI00JVW ST38L_HUMAN Increases Expression [9]
Small kinetochore-associated protein (KNSTRN) OTYA7UXS SKAP_HUMAN Decreases Expression [9]
Origin recognition complex subunit 6 (ORC6) OTKQN3KP ORC6_HUMAN Decreases Expression [9]
Phosphoserine aminotransferase (PSAT1) OTVV1YV9 SERC_HUMAN Increases Expression [9]
Carboxypeptidase Q (CPQ) OTTNZNLD CBPQ_HUMAN Increases Expression [9]
Transforming acidic coiled-coil-containing protein 3 (TACC3) OTRNEZTA TACC3_HUMAN Decreases Expression [9]
Inositol 1,4,5-triphosphate receptor associated 1 (IRAG1) OTMRW5U5 IRAG1_HUMAN Increases Expression [9]
Adenylate kinase isoenzyme 5 (AK5) OTTGXLOT KAD5_HUMAN Decreases Expression [9]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Decreases Activity [17]
Alkyldihydroxyacetonephosphate synthase, peroxisomal (AGPS) OTFBFPV4 ADAS_HUMAN Increases Expression [18]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Decreases Expression [18]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [18]
Phosphatidylinositol 3-kinase regulatory subunit alpha (PIK3R1) OT5BZ1J9 P85A_HUMAN Decreases Phosphorylation [18]
RAC-alpha serine/threonine-protein kinase (AKT1) OT8H2YY7 AKT1_HUMAN Decreases Phosphorylation [18]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Decreases Expression [18]
cAMP-regulated phosphoprotein 19 (ARPP19) OTZS3IT6 ARP19_HUMAN Increases Expression [18]
Interferon-induced protein with tetratricopeptide repeats 3 (IFIT3) OTPGHZB9 IFIT3_HUMAN Increases Expression [19]
Apoptosis-inducing factor 1, mitochondrial (AIFM1) OTKPWB7Q AIFM1_HUMAN Affects Localization [20]
Tyrosine-protein kinase ABL1 (ABL1) OT09YVXH ABL1_HUMAN Decreases Activity [21]
Myc proto-oncogene protein (MYC) OTPV5LUK MYC_HUMAN Decreases Expression [19]
Transforming growth factor beta-1 proprotein (TGFB1) OTV5XHVH TGFB1_HUMAN Decreases Activity [22]
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Decreases Expression [23]
Interferon gamma (IFNG) OTXG9JM7 IFNG_HUMAN Decreases Expression [23]
C-X-C motif chemokine 10 (CXCL10) OTTLQ6S0 CXL10_HUMAN Increases Expression [19]
Granulocyte-macrophage colony-stimulating factor (CSF2) OT1M7D28 CSF2_HUMAN Decreases Expression [23]
Cytochrome P450 1A1 (CYP1A1) OTE4EFH8 CP1A1_HUMAN Decreases Activity [24]
Interleukin-5 (IL5) OTAFPSCO IL5_HUMAN Decreases Expression [23]
Cathepsin B (CTSB) OTP9G5QB CATB_HUMAN Decreases Expression [25]
Tyrosine-protein kinase Lyn (LYN) OTP686K2 LYN_HUMAN Decreases Activity [10]
Hepatocyte growth factor receptor (MET) OT7K55MU MET_HUMAN Decreases Phosphorylation [26]
Growth-regulated alpha protein (CXCL1) OT3WCTZV GROA_HUMAN Decreases Expression [23]
High mobility group protein B1 (HMGB1) OT4B7CPF HMGB1_HUMAN Increases Expression [27]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Decreases Activity [25]
C-C motif chemokine 3 (CCL3) OTW2H3ND CCL3_HUMAN Decreases Expression [23]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Decreases Expression [28]
Mast/stem cell growth factor receptor Kit (KIT) OTHUY3VZ KIT_HUMAN Decreases Phosphorylation [29]
Integrin alpha-M (ITGAM) OTAG6HWU ITAM_HUMAN Increases Expression [19]
Breakpoint cluster region protein (BCR) OTCN76C1 BCR_HUMAN Decreases Activity [21]
C-C motif chemokine 4 (CCL4) OT6B8P25 CCL4_HUMAN Decreases Expression [23]
C-C motif chemokine 2 (CCL2) OTAD2HEL CCL2_HUMAN Decreases Activity [25]
C-C motif chemokine 5 (CCL5) OTSCA5CK CCL5_HUMAN Decreases Expression [23]
Interleukin-1 receptor type 1 (IL1R1) OTTU8959 IL1R1_HUMAN Decreases Expression [23]
Platelet-derived growth factor receptor alpha (PDGFRA) OTDJXUCN PGFRA_HUMAN Decreases Phosphorylation [30]
C-C motif chemokine 1 (CCL1) OT23NON8 CCL1_HUMAN Decreases Expression [23]
G1/S-specific cyclin-D1 (CCND1) OT8HPTKJ CCND1_HUMAN Decreases Expression [31]
Mitogen-activated protein kinase 3 (MAPK3) OTCYKGKO MK03_HUMAN Decreases Phosphorylation [10]
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Decreases Phosphorylation [10]
ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38) OTG0TTX7 CD38_HUMAN Decreases Expression [23]
G1/S-specific cyclin-D3 (CCND3) OTNKPQ22 CCND3_HUMAN Decreases Expression [31]
Receptor-type tyrosine-protein kinase FLT3 (FLT3) OTMSRYMK FLT3_HUMAN Decreases Phosphorylation [29]
Signal transducer and activator of transcription 3 (STAT3) OTAAGKYZ STAT3_HUMAN Decreases Phosphorylation [32]
Serine/threonine-protein kinase mTOR (MTOR) OTHH8KU7 MTOR_HUMAN Decreases Phosphorylation [28]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Activity [21]
Tyrosine-protein kinase ABL2 (ABL2) OTS8F4GD ABL2_HUMAN Affects Binding [33]
Crk-like protein (CRKL) OTOYSD1R CRKL_HUMAN Decreases Phosphorylation [34]
Cyclin-dependent kinase inhibitor 1B (CDKN1B) OTNY5LLZ CDN1B_HUMAN Increases Expression [31]
Stromal cell-derived factor 1 (CXCL12) OT2QX5LL SDF1_HUMAN Decreases Expression [23]
Paxillin (PXN) OTVMMUOF PAXI_HUMAN Decreases Phosphorylation [32]
Caspase-7 (CASP7) OTAPJ040 CASP7_HUMAN Increases Cleavage [10]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Increases Activity [35]
Interleukin-2 (IL2) OTGI4NSA IL2_HUMAN Decreases Expression [23]
Small ribosomal subunit protein eS6 (RPS6) OTT4D1LN RS6_HUMAN Decreases Phosphorylation [23]
Mothers against decapentaplegic homolog 3 (SMAD3) OTNA96MR SMAD3_HUMAN Decreases Phosphorylation [22]
Dual specificity mitogen-activated protein kinase kinase 1 (MAP2K1) OT4Y9NQI MP2K1_HUMAN Increases Phosphorylation [19]
Focal adhesion kinase 1 (PTK2) OT3Q1JDY FAK1_HUMAN Decreases Phosphorylation [31]
Early activation antigen CD69 (CD69) OTGJHSVP CD69_HUMAN Decreases Expression [23]
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Decreases Expression [10]
Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) OT2YYI1A MCL1_HUMAN Decreases Expression [10]
Caspase-8 (CASP8) OTA8TVI8 CASP8_HUMAN Increases Activity [35]
Pre-mRNA 3'-end-processing factor FIP1 (FIP1L1) OTF91GTL FIP1_HUMAN Decreases Phosphorylation [30]
Bile acid receptor (NR1H4) OTWZLPTB NR1H4_HUMAN Decreases Phosphorylation [36]
Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase (PKMYT1) OTYRXD2T PMYT1_HUMAN Decreases Activity [37]
Transcription factor SOX-17 (SOX17) OT9H4WWE SOX17_HUMAN Decreases Localization [38]
Diablo IAP-binding mitochondrial protein (DIABLO) OTHJ9MCZ DBLOH_HUMAN Affects Localization [20]
Epidermal growth factor receptor (EGFR) OTAPLO1S EGFR_HUMAN Increases Response To Substance [31]
Sterol-4-alpha-carboxylate 3-dehydrogenase, decarboxylating (NSDHL) OTK3EJFD NSDHL_HUMAN Decreases Response To Substance [39]
Methylsterol monooxygenase 1 (MSMO1) OTKV62RZ MSMO1_HUMAN Decreases Response To Substance [39]
------------------------------------------------------------------------------------
⏷ Show the Full List of 453 DOT(s)
Indication(s) of Sorafenib
Disease Entry ICD 11 Status REF
Adenocarcinoma 2D40 Approved [6]
Carcinoma 2A00-2F9Z Approved [6]
Clear cell renal carcinoma N.A. Approved [6]
Lung cancer 2C25.0 Approved [6]
Medullary thyroid gland carcinoma N.A. Approved [6]
Non-small-cell lung cancer 2C25.Y Approved [6]
Renal cell carcinoma 2C90 Approved [7]
Thyroid cancer 2D10 Approved [6]
Hepatocellular carcinoma 2C12.02 Phase 3 [7]
Myelodysplastic syndrome 2A37 Phase 2 [7]
Sorafenib Interacts with 4 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Tyrosine-protein kinase Kit (KIT) TTX41N9 KIT_HUMAN Modulator [45]
Platelet-derived growth factor receptor beta (PDGFRB) TTI7421 PGFRB_HUMAN Modulator [45]
Epidermal growth factor receptor (EGFR) TTGKNB4 EGFR_HUMAN Inhibitor [46]
Vascular endothelial growth factor receptor 2 (KDR) TTUTJGQ VGFR2_HUMAN Modulator [45]
------------------------------------------------------------------------------------
Sorafenib Interacts with 7 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [47]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [48]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [49]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [14]
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [50]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [14]
RalBP1-associated Eps domain-containing protein 2 (RALBP1) DTYEM9B REPS2_HUMAN Substrate [51]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 DTP(s)
Sorafenib Interacts with 6 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [52]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Metabolism [53]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [54]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Metabolism [54]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Metabolism [52]
UDP-glucuronosyltransferase 1A9 (UGT1A9) DE85D2P UD19_HUMAN Metabolism [55]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 DME(s)
Sorafenib Interacts with 112 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 2C8 (CYP2C8) OTHCWT42 CP2C8_HUMAN Decreases Activity [56]
ATP-binding cassette sub-family C member 2 (ABCC2) OTJSIGV5 MRP2_HUMAN Affects Response To Substance [57]
Mast/stem cell growth factor receptor Kit (KIT) OTHUY3VZ KIT_HUMAN Decreases Phosphorylation [58]
NF-kappa-B inhibitor alpha (NFKBIA) OTFT924M IKBA_HUMAN Increases Expression [59]
DNA damage-inducible transcript 3 protein (DDIT3) OTI8YKKE DDIT3_HUMAN Increases Expression [60]
DNA damage-inducible transcript 4 protein (DDIT4) OTHY8SY4 DDIT4_HUMAN Increases Expression [60]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Decreases Activity [61]
Mitogen-activated protein kinase 3 (MAPK3) OTCYKGKO MK03_HUMAN Decreases Activity [62]
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Decreases Activity [62]
Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha (PIK3C2A) OTFBU4GD P3C2A_HUMAN Decreases Expression [40]
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Decreases Expression [40]
Epidermal growth factor receptor (EGFR) OTAPLO1S EGFR_HUMAN Decreases Expression [40]
GTPase NRas (NRAS) OTVQ1DG3 RASN_HUMAN Decreases Expression [40]
Insulin-like growth factor 1 receptor (IGF1R) OTXJIF13 IGF1R_HUMAN Decreases Expression [40]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Decreases Expression [40]
Protein kinase C alpha type (PRKCA) OT5UWNRD KPCA_HUMAN Decreases Expression [40]
Cyclin-dependent kinase 2 (CDK2) OTB5DYYZ CDK2_HUMAN Decreases Expression [40]
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (PIK3CA) OTTOMI8J PK3CA_HUMAN Decreases Expression [40]
Serine/threonine-protein kinase mTOR (MTOR) OTHH8KU7 MTOR_HUMAN Decreases Expression [40]
Cyclin-dependent kinase 9 (CDK9) OT2B7OGB CDK9_HUMAN Decreases Expression [40]
Growth factor receptor-bound protein 2 (GRB2) OTOP7LTE GRB2_HUMAN Decreases Expression [40]
E3 ubiquitin-protein ligase Mdm2 (MDM2) OTOVXARF MDM2_HUMAN Increases Expression [40]
Interferon regulatory factor 5 (IRF5) OT8SIIAP IRF5_HUMAN Increases Expression [40]
Hypoxia-inducible factor 1-alpha (HIF1A) OTADSC03 HIF1A_HUMAN Decreases Expression [40]
Serine/threonine-protein kinase PLK3 (PLK3) OT19CT2Z PLK3_HUMAN Increases Expression [40]
Serine/threonine-protein kinase PLK2 (PLK2) OTKMJXJ8 PLK2_HUMAN Increases Expression [40]
Histone deacetylase 6 (HDAC6) OT9W9MXQ HDAC6_HUMAN Decreases Expression [40]
Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B) OTA1CPBV TR10B_HUMAN Increases Expression [60]
CASP8 and FADD-like apoptosis regulator (CFLAR) OTX14BAS CFLAR_HUMAN Decreases Expression [63]
Bcl-2-like protein 11 (BCL2L11) OTNQQWFJ B2L11_HUMAN Decreases Expression [64]
Zinc finger protein SNAI2 (SNAI2) OT7Y8EJ2 SNAI2_HUMAN Decreases Expression [41]
E3 ubiquitin-protein ligase parkin (PRKN) OTJBN41W PRKN_HUMAN Increases Ubiquitination [65]
Growth arrest and DNA damage-inducible protein GADD45 beta (GADD45B) OTL9I7LO GA45B_HUMAN Increases Expression [66]
Protein phosphatase 1 regulatory subunit 15A (PPP1R15A) OTYG179K PR15A_HUMAN Increases Expression [42]
Growth arrest and DNA damage-inducible protein GADD45 gamma (GADD45G) OT8V1J4M GA45G_HUMAN Increases Expression [67]
Apoptosis-inducing factor 1, mitochondrial (AIFM1) OTKPWB7Q AIFM1_HUMAN Affects Localization [64]
Tyrosine-protein kinase ABL1 (ABL1) OT09YVXH ABL1_HUMAN Decreases Activity [68]
Urokinase-type plasminogen activator (PLAU) OTX0QGKK UROK_HUMAN Decreases Expression [69]
Transforming growth factor beta-1 proprotein (TGFB1) OTV5XHVH TGFB1_HUMAN Decreases Activity [70]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Increases Secretion [71]
RAF proto-oncogene serine/threonine-protein kinase (RAF1) OT51LSFO RAF1_HUMAN Decreases Activity [58]
Cytochrome P450 1A1 (CYP1A1) OTE4EFH8 CP1A1_HUMAN Decreases Expression [72]
Transcription factor Jun (JUN) OTCYBO6X JUN_HUMAN Increases Expression [66]
Tyrosine-protein kinase Lck (LCK) OT883FG9 LCK_HUMAN Decreases Phosphorylation [73]
Retinoblastoma-associated protein (RB1) OTQJUJMZ RB_HUMAN Decreases Expression [74]
Eukaryotic translation initiation factor 4E (EIF4E) OTDAWNLA IF4E_HUMAN Decreases Phosphorylation [64]
Proto-oncogene tyrosine-protein kinase receptor Ret (RET) OTLU040A RET_HUMAN Decreases Activity [75]
High mobility group protein B1 (HMGB1) OT4B7CPF HMGB1_HUMAN Increases Expression [71]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [76]
Breakpoint cluster region protein (BCR) OTCN76C1 BCR_HUMAN Decreases Activity [68]
Cytochrome P450 2C9 (CYP2C9) OTGLBN29 CP2C9_HUMAN Decreases Activity [56]
Cyclin-dependent kinase 4 (CDK4) OT7EP05T CDK4_HUMAN Decreases Expression [77]
Cadherin-1 (CDH1) OTFJMXPM CADH1_HUMAN Increases Expression [41]
Proto-oncogene tyrosine-protein kinase Src (SRC) OTETYX40 SRC_HUMAN Decreases Activity [78]
Serine/threonine-protein kinase B-raf (BRAF) OT7S81XQ BRAF_HUMAN Decreases Activity [79]
Platelet-derived growth factor receptor alpha (PDGFRA) OTDJXUCN PGFRA_HUMAN Decreases Phosphorylation [80]
Cyclic AMP-dependent transcription factor ATF-4 (ATF4) OTRFV19J ATF4_HUMAN Increases Expression [60]
Ribosomal protein S6 kinase beta-1 (RPS6KB1) OTAELNGX KS6B1_HUMAN Decreases Phosphorylation [81]
Alanine aminotransferase 1 (GPT) OTOXOA0Q ALAT1_HUMAN Increases Secretion [82]
G1/S-specific cyclin-D1 (CCND1) OT8HPTKJ CCND1_HUMAN Decreases Expression [83]
G1/S-specific cyclin-D2 (CCND2) OTDULQF9 CCND2_HUMAN Decreases Expression [83]
G1/S-specific cyclin-D3 (CCND3) OTNKPQ22 CCND3_HUMAN Decreases Expression [77]
RAC-alpha serine/threonine-protein kinase (AKT1) OT8H2YY7 AKT1_HUMAN Decreases Expression [84]
Vascular endothelial growth factor receptor 2 (KDR) OT15797V VGFR2_HUMAN Decreases Phosphorylation [58]
Dual specificity mitogen-activated protein kinase kinase 2 (MAP2K2) OTUE7Z91 MP2K2_HUMAN Decreases Phosphorylation [79]
Signal transducer and activator of transcription 3 (STAT3) OTAAGKYZ STAT3_HUMAN Decreases Phosphorylation [85]
Signal transducer and activator of transcription 5A (STAT5A) OTBSJGN3 STA5A_HUMAN Decreases Activity [86]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Decreases Expression [87]
Mitogen-activated protein kinase 8 (MAPK8) OTEREYS5 MK08_HUMAN Decreases Phosphorylation [69]
Mitogen-activated protein kinase 9 (MAPK9) OTCEVJ9E MK09_HUMAN Decreases Phosphorylation [69]
Dual specificity mitogen-activated protein kinase kinase 4 (MAP2K4) OTZPZX11 MP2K4_HUMAN Decreases Phosphorylation [69]
Crk-like protein (CRKL) OTOYSD1R CRKL_HUMAN Decreases Phosphorylation [68]
Cyclin-dependent kinase inhibitor 1B (CDKN1B) OTNY5LLZ CDN1B_HUMAN Increases Expression [88]
CCAAT/enhancer-binding protein delta (CEBPD) OTNBIPMY CEBPD_HUMAN Increases Expression [67]
Glycogen synthase kinase-3 beta (GSK3B) OTL3L14B GSK3B_HUMAN Increases Phosphorylation [87]
Tumor necrosis factor ligand superfamily member 10 (TNFSF10) OT4PXBTA TNF10_HUMAN Increases Response To Substance [89]
Stanniocalcin-1 (STC1) OTGVVXYF STC1_HUMAN Decreases Expression [90]
Caspase-7 (CASP7) OTAPJ040 CASP7_HUMAN Increases Activity [91]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Increases Activity [73]
Gasdermin-D (GSDMD) OTH39BKI GSDMD_HUMAN Increases Expression [71]
Sestrin-2 (SESN2) OT889IXY SESN2_HUMAN Increases Expression [92]
Small ribosomal subunit protein eS6 (RPS6) OTT4D1LN RS6_HUMAN Decreases Phosphorylation [93]
Cytochrome c (CYCS) OTBFALJD CYC_HUMAN Affects Localization [94]
Cyclin-dependent kinase 6 (CDK6) OTR95N0X CDK6_HUMAN Decreases Expression [77]
Dual specificity mitogen-activated protein kinase kinase 1 (MAP2K1) OT4Y9NQI MP2K1_HUMAN Decreases Phosphorylation [79]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Increases Cleavage [64]
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Decreases Expression [64]
Potassium voltage-gated channel subfamily H member 2 (KCNH2) OTZX881H KCNH2_HUMAN Decreases Activity [95]
Baculoviral IAP repeat-containing protein 3 (BIRC3) OT3E95KB BIRC3_HUMAN Decreases Expression [96]
Sequestosome-1 (SQSTM1) OTGY5D5J SQSTM_HUMAN Decreases Expression [81]
Eukaryotic translation initiation factor 4E-binding protein 1 (EIF4EBP1) OTHBQVD5 4EBP1_HUMAN Decreases Phosphorylation [97]
Phorbol-12-myristate-13-acetate-induced protein 1 (PMAIP1) OTXEE550 APR_HUMAN Decreases Expression [98]
Caspase-8 (CASP8) OTA8TVI8 CASP8_HUMAN Increases Cleavage [43]
Mitogen-activated protein kinase 14 (MAPK14) OT5TCO3O MK14_HUMAN Decreases Expression [99]
Bcl-2 homologous antagonist/killer (BAK1) OTDP6ILW BAK_HUMAN Decreases Expression [64]
Cytochrome P450 1B1 (CYP1B1) OTYXFLSD CP1B1_HUMAN Decreases Activity [24]
Bcl2-associated agonist of cell death (BAD) OT63ERYM BAD_HUMAN Increases Expression [43]
Docking protein 1 (DOK1) OTGVRLW6 DOK1_HUMAN Decreases Phosphorylation [68]
Serine/threonine-protein kinase PINK1, mitochondrial (PINK1) OT50NR57 PINK1_HUMAN Increases Expression [65]
Eukaryotic translation initiation factor 2A (EIF2A) OTWXELQP EIF2A_HUMAN Increases Phosphorylation [42]
Autophagy protein 5 (ATG5) OT4T5SMS ATG5_HUMAN Increases Expression [100]
Transcription factor SOX-17 (SOX17) OT9H4WWE SOX17_HUMAN Decreases Localization [38]
Ubiquitin carboxyl-terminal hydrolase CYLD (CYLD) OT37FKH0 CYLD_HUMAN Increases Expression [59]
Diablo IAP-binding mitochondrial protein (DIABLO) OTHJ9MCZ DBLOH_HUMAN Affects Localization [98]
Eukaryotic translation initiation factor 2-alpha kinase 3 (EIF2AK3) OT0DZGY4 E2AK3_HUMAN Increases Phosphorylation [42]
E3 ubiquitin-protein ligase TRIM62 (TRIM62) OT15YO6N TRI62_HUMAN Affects Response To Substance [101]
Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) OT2YYI1A MCL1_HUMAN Decreases Response To Substance [64]
ATP-binding cassette sub-family C member 3 (ABCC3) OTC3IJV4 MRP3_HUMAN Affects Response To Substance [57]
Hepatocyte growth factor (HGF) OTGHUA23 HGF_HUMAN Decreases Response To Substance [102]
Multidrug resistance-associated protein 1 (ABCC1) OTGUN89S MRP1_HUMAN Affects Response To Substance [57]
Receptor-type tyrosine-protein kinase FLT3 (FLT3) OTMSRYMK FLT3_HUMAN Increases Response To Substance [93]
Na(+)/citrate cotransporter (SLC13A5) OTPH1TA7 S13A5_HUMAN Decreases Response To Substance [103]
------------------------------------------------------------------------------------
⏷ Show the Full List of 112 DOT(s)

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adenocarcinoma DCXSWSZ CAOV3 Investigative [1]
Adenocarcinoma DC9X8QK OVCAR3 Investigative [1]
Adenocarcinoma DCCCU9Q A427 Investigative [1]
Adenocarcinoma DCQ7GXO NCIH1650 Investigative [1]
Adenocarcinoma DCO14B8 NCIH23 Investigative [1]
Adenocarcinoma DCE1S15 NCIH520 Investigative [1]
Adenocarcinoma DCJEW73 DLD1 Investigative [1]
Adenocarcinoma DCVS3H6 HCT116 Investigative [1]
Adenocarcinoma DCLLEET HT29 Investigative [1]
Adenocarcinoma DCQNDQ8 SW-620 Investigative [1]
Amelanotic melanoma DCMZXQH A2058 Investigative [1]
Ewing sarcoma-peripheral primitive neuroectodermal tumour DCDEG3K ES2 Investigative [1]
Germ cell tumour DC85O0I PA1 Investigative [1]
Malignant melanoma DCOB7GO A375 Investigative [1]
Malignant melanoma DCY3XRM HT144 Investigative [1]
Malignant melanoma DCSXMBR UACC62 Investigative [1]
Melanoma DCZRRSL MALME-3M Investigative [1]
Mesothelioma DCJ8PZK MSTO Investigative [1]
Ovarian endometrioid adenocarcinoma DCTAHEJ A2780 Investigative [1]
Ovarian serous cystadenocarcinoma DCSR4NY SK-OV-3 Investigative [1]
Prostate carcinoma DCXQRCU VCAP Investigative [1]
Breast carcinoma DCLKBFY ZR751 Investigative [104]
Breast carcinoma DC49JME KPL1 Investigative [104]
Breast carcinoma DCRJ623 OCUBM Investigative [104]
Carcinoma DC8O8G8 OV90 Investigative [104]
Carcinoma DC7F6YQ EFM192B Investigative [104]
Carcinoma DC21LDO MDAMB436 Investigative [104]
Colon adenocarcinoma DCKS7GZ LOVO Investigative [104]
Colon carcinoma DCNT15U RKO Investigative [104]
Invasive ductal carcinoma DC07SWA T-47D Investigative [104]
------------------------------------------------------------------------------------
⏷ Show the Full List of 30 DrugCom(s)

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Dasatinib FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5678).
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
5 Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
6 Sorafenib FDA Label
7 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5711).
8 The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils. Blood. 2008 Mar 15;111(6):3097-107.
9 Dasatinib reverses cancer-associated fibroblasts (CAFs) from primary lung carcinomas to a phenotype comparable to that of normal fibroblasts. Mol Cancer. 2010 Jun 27;9:168.
10 The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes. Blood. 2008 Aug 15;112(4):1443-52. doi: 10.1182/blood-2007-11-123984. Epub 2008 Jun 12.
11 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
12 Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos. 2010 Aug;38(8):1371-80.
13 Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol. 2009 Oct;158(4):1153-64.
14 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
15 Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706.
16 Identification of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics. Drug Metab Dispos. 2008 Sep;36(9):1828-39.
17 A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci. 2013 Nov;136(1):216-41.
18 Combination of arsenic trioxide and Dasatinib: a new strategy to treat Philadelphia chromosome-positive acute lymphoblastic leukaemia. J Cell Mol Med. 2018 Mar;22(3):1614-1626.
19 MEK/ERK dependent activation of STAT1 mediates dasatinib-induced differentiation of acute myeloid leukemia. PLoS One. 2013 Jun 25;8(6):e66915. doi: 10.1371/journal.pone.0066915. Print 2013.
20 Co-administration of NVP-AEW541 and dasatinib induces mitochondrial-mediated apoptosis through Bax activation in malignant human glioma cell lines. Int J Oncol. 2010 Sep;37(3):633-43. doi: 10.3892/ijo_00000712.
21 Combined BCR-ABL inhibition with lentiviral-delivered shRNA and dasatinib augments induction of apoptosis in Philadelphia-positive cells. Exp Hematol. 2009 Feb;37(2):206-14. doi: 10.1016/j.exphem.2008.10.013. Epub 2008 Dec 18.
22 Identification and Profiling of Environmental Chemicals That Inhibit the TGF/SMAD Signaling Pathway. Chem Res Toxicol. 2019 Dec 16;32(12):2433-2444. doi: 10.1021/acs.chemrestox.9b00228. Epub 2019 Nov 11.
23 Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood. 2008 Feb 1;111(3):1366-77. doi: 10.1182/blood-2007-04-084814. Epub 2007 Oct 25.
24 Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
25 IL-8 and MCP-1/CCL2 regulate proteolytic activity in triple negative inflammatory breast cancer a mechanism that might be modulated by Src and Erk1/2. Toxicol Appl Pharmacol. 2020 Aug 15;401:115092. doi: 10.1016/j.taap.2020.115092. Epub 2020 Jun 5.
26 Distinct interactions between c-Src and c-Met in mediating resistance to c-Src inhibition in head and neck cancer. Clin Cancer Res. 2011 Feb 1;17(3):514-24. doi: 10.1158/1078-0432.CCR-10-1617. Epub 2010 Nov 24.
27 High-mobility group box 1 protein-mediated necroptosis contributes to dasatinib-induced cardiotoxicity. Toxicol Lett. 2018 Oct 15;296:39-47. doi: 10.1016/j.toxlet.2018.08.003. Epub 2018 Aug 4.
28 Dasatinib induces autophagic cell death in human ovarian cancer. Cancer. 2010 Nov 1;116(21):4980-90. doi: 10.1002/cncr.25426.
29 Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias. Clin Cancer Res. 2010 Feb 15;16(4):1149-58. doi: 10.1158/1078-0432.CCR-09-2416. Epub 2010 Feb 9.
30 Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRalpha. Exp Hematol. 2008 Oct;36(10):1244-53. doi: 10.1016/j.exphem.2008.04.017. Epub 2008 Jul 10.
31 Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res. 2006 Jun 1;66(11):5542-8. doi: 10.1158/0008-5472.CAN-05-4620.
32 Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis. Mol Cancer Ther. 2010 Aug;9(8):2322-32. doi: 10.1158/1535-7163.MCT-09-1212. Epub 2010 Aug 3.
33 The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci U S A. 2007 Aug 14;104(33):13283-8. doi: 10.1073/pnas.0702654104. Epub 2007 Aug 7.
34 Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells. Clin Cancer Res. 2006 Oct 1;12(19):5869-78. doi: 10.1158/1078-0432.CCR-06-0980.
35 Src inhibitor dasatinib inhibits growth of breast cancer cells by modulating EGFR signaling. Cancer Lett. 2009 Oct 8;283(2):143-51. doi: 10.1016/j.canlet.2009.03.035. Epub 2009 Apr 26.
36 Phosphorylation of hepatic farnesoid X receptor by FGF19 signaling-activated Src maintains cholesterol levels and protects from atherosclerosis. J Biol Chem. 2019 May 31;294(22):8732-8744. doi: 10.1074/jbc.RA119.008360. Epub 2019 Apr 17.
37 Identification of PKMYT1 inhibitors by screening the GSK published protein kinase inhibitor set I and II. Bioorg Med Chem. 2018 Aug 7;26(14):4014-4024. doi: 10.1016/j.bmc.2018.06.027. Epub 2018 Jun 20.
38 A high-throughput screen for teratogens using human pluripotent stem cells. Toxicol Sci. 2014 Jan;137(1):76-90. doi: 10.1093/toxsci/kft239. Epub 2013 Oct 23.
39 Targeting C4-demethylating genes in the cholesterol pathway sensitizes cancer cells to EGF receptor inhibitors via increased EGF receptor degradation. Cancer Discov. 2013 Jan;3(1):96-111. doi: 10.1158/2159-8290.CD-12-0031. Epub 2012 Nov 2.
40 Novel carbocyclic curcumin analog CUR3d modulates genes involved in multiple apoptosis pathways in human hepatocellular carcinoma cells. Chem Biol Interact. 2015 Dec 5;242:107-22.
41 Destruxin B inhibits hepatocellular carcinoma cell growth through modulation of the Wnt/-catenin signaling pathway and epithelial-mesenchymal transition. Toxicol In Vitro. 2014 Jun;28(4):552-61. doi: 10.1016/j.tiv.2014.01.002. Epub 2014 Jan 13.
42 The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress. Mol Cell Biol. 2007 Aug;27(15):5499-513. doi: 10.1128/MCB.01080-06. Epub 2007 Jun 4.
43 Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. Leukemia. 2008 Apr;22(4):808-18. doi: 10.1038/sj.leu.2405098. Epub 2008 Jan 17.
44 Ovatodiolide suppresses yes-associated protein 1-modulated cancer stem cell phenotypes in highly malignant hepatocellular carcinoma and sensitizes cancer cells to chemotherapy in vitro. Toxicol In Vitro. 2018 Sep;51:74-82. doi: 10.1016/j.tiv.2018.04.010. Epub 2018 Apr 24.
45 Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40.
46 Nasopharyngeal carcinoma: Current treatment options and future directions. J Nasopharyng Carcinoma, 2014, 1(16): e16.
47 Multidrug resistance protein 2 implicates anticancer drug-resistance to sorafenib. Biol Pharm Bull. 2011;34(3):433-5.
48 Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation. Mol Cancer Ther. 2010 Feb;9(2):319-26.
49 Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier. Mol Pharm. 2011 Apr 4;8(2):571-82.
50 Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma
51 Rlip76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer. Int J Cancer. 2010 Mar 15;126(6):1327-38.
52 Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
53 Ontogeny and sorafenib metabolism. Clin Cancer Res. 2012 Oct 15;18(20):5788-95.
54 Drug Interactions Flockhart Table
55 Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. Invest New Drugs. 2011 Dec;29(6):1511-4.
56 Differential inhibition of human CYP2C8 and molecular docking interactions elicited by sorafenib and its major N-oxide metabolite. Chem Biol Interact. 2021 Apr 1;338:109401. doi: 10.1016/j.cbi.2021.109401. Epub 2021 Feb 5.
57 The Enhanced metastatic potential of hepatocellular carcinoma (HCC) cells with sorafenib resistance. PLoS One. 2013 Nov 11;8(11):e78675. doi: 10.1371/journal.pone.0078675. eCollection 2013.
58 Sorafenib induces growth suppression in mouse models of gastrointestinal stromal tumor. Mol Cancer Ther. 2009 Jan;8(1):152-9. doi: 10.1158/1535-7163.MCT-08-0553.
59 Down-regulation of CYLD as a trigger for NF-B activation and a mechanism of apoptotic resistance in hepatocellular carcinoma cells. Int J Oncol. 2011 Jan;38(1):121-31.
60 Sorafenib induces apoptotic cell death in human non-small cell lung cancer cells by down-regulating mammalian target of rapamycin (mTOR)-dependent survivin expression. Biochem Pharmacol. 2011 Aug 1;82(3):216-26. doi: 10.1016/j.bcp.2011.04.011. Epub 2011 May 13.
61 Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
62 Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines. BMC Cancer. 2012 Sep 10;12:402.
63 The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. Cancer Res. 2007 Oct 1;67(19):9490-500. doi: 10.1158/0008-5472.CAN-07-0598.
64 Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J Biol Chem. 2005 Oct 21;280(42):35217-27. doi: 10.1074/jbc.M506551200. Epub 2005 Aug 18.
65 Sorafenib targets the mitochondrial electron transport chain complexes and ATP synthase to activate the PINK1-Parkin pathway and modulate cellular drug response. J Biol Chem. 2017 Sep 8;292(36):15105-15120. doi: 10.1074/jbc.M117.783175. Epub 2017 Jul 3.
66 Induction of DNA damage-inducible gene GADD45beta contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells. Cancer Res. 2010 Nov 15;70(22):9309-18. doi: 10.1158/0008-5472.CAN-10-1033. Epub 2010 Nov 9.
67 Growth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma. Oncotarget. 2015 Sep 29;6(29):27953-65. doi: 10.18632/oncotarget.4446.
68 Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway. Cancer Res. 2009 May 1;69(9):3927-36. doi: 10.1158/0008-5472.CAN-08-2978. Epub 2009 Apr 14.
69 Synergistic antimetastatic effect of cotreatment with licochalcone A and sorafenib on human hepatocellular carcinoma cells through the inactivation of MKK4/JNK and uPA expression. Environ Toxicol. 2018 Dec;33(12):1237-1244. doi: 10.1002/tox.22630. Epub 2018 Sep 6.
70 Sorafenib inhibits transforming growth factor 1-mediated epithelial-mesenchymal transition and apoptosis in mouse hepatocytes. Hepatology. 2011 May;53(5):1708-18. doi: 10.1002/hep.24254.
71 Activation of inflammasomes by tyrosine kinase inhibitors of vascular endothelial growth factor receptor: Implications for VEGFR TKIs-induced immune related adverse events. Toxicol In Vitro. 2021 Mar;71:105063. doi: 10.1016/j.tiv.2020.105063. Epub 2020 Dec 1.
72 Sorafenib is an antagonist of the aryl hydrocarbon receptor. Toxicology. 2022 Mar 30;470:153118. doi: 10.1016/j.tox.2022.153118. Epub 2022 Feb 3.
73 Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1. Leukemia. 2011 May;25(5):838-47. doi: 10.1038/leu.2011.2. Epub 2011 Feb 4.
74 Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. Cancer Res. 2007 Oct 1;67(19):9443-54. doi: 10.1158/0008-5472.CAN-07-1473.
75 Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting. J Biol Chem. 2007 Oct 5;282(40):29230-40. doi: 10.1074/jbc.M703461200. Epub 2007 Jul 30.
76 Synergistic activity of letrozole and sorafenib on breast cancer cells. Breast Cancer Res Treat. 2010 Nov;124(1):79-88. doi: 10.1007/s10549-009-0714-5. Epub 2010 Jan 7.
77 Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells. J Pharmacol Exp Ther. 2006 Dec;319(3):1070-80. doi: 10.1124/jpet.106.108621. Epub 2006 Sep 7.
78 Sorafenib induces apoptosis in HL60 cells by inhibiting Src kinase-mediated STAT3 phosphorylation. Anticancer Drugs. 2011 Jan;22(1):79-88. doi: 10.1097/CAD.0b013e32833f44fd.
79 Rap1/B-Raf signaling is activated in neuroendocrine tumors of the digestive tract and Raf kinase inhibition constitutes a putative therapeutic target. Neuroendocrinology. 2007;85(1):45-53. doi: 10.1159/000100508. Epub 2007 Mar 5.
80 Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies. Mol Cancer Ther. 2011 Jun;10(6):1028-35. doi: 10.1158/1535-7163.MCT-10-1044. Epub 2011 Apr 11.
81 Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma. Int J Cancer. 2012 Aug 1;131(3):548-57. doi: 10.1002/ijc.26374. Epub 2011 Sep 12.
82 Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes. Toxicol Lett. 2018 Jul;291:138-148. doi: 10.1016/j.toxlet.2018.04.010. Epub 2018 Apr 12.
83 Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas. Mol Cancer Ther. 2008 Nov;7(11):3519-26. doi: 10.1158/1535-7163.MCT-08-0138.
84 Therapeutic targeting of hepatocellular carcinoma cells with antrocinol, a novel, dual-specificity, small-molecule inhibitor of the KRAS and ERK oncogenic signaling pathways. Chem Biol Interact. 2023 Jan 25;370:110329. doi: 10.1016/j.cbi.2022.110329. Epub 2022 Dec 22.
85 Sorafenib derivatives induce apoptosis through inhibition of STAT3 independent of Raf. Eur J Med Chem. 2011 Jul;46(7):2845-51. doi: 10.1016/j.ejmech.2011.04.007. Epub 2011 Apr 14.
86 The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation. Mol Pharmacol. 2007 Sep;72(3):788-95. doi: 10.1124/mol.106.033308. Epub 2007 Jun 26.
87 Arsenic trioxide potentiates the anti-cancer activities of sorafenib against hepatocellular carcinoma by inhibiting Akt activation. Tumour Biol. 2015 Apr;36(4):2323-34. doi: 10.1007/s13277-014-2839-3. Epub 2014 Nov 22.
88 Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations. BMC Cancer. 2009 Oct 31;9:387. doi: 10.1186/1471-2407-9-387.
89 The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms. Eur J Cancer. 2010 Mar;46(4):836-50. doi: 10.1016/j.ejca.2009.12.025. Epub 2010 Jan 12.
90 Downregulation of stanniocalcin 1 is responsible for sorafenib-induced cardiotoxicity. Toxicol Sci. 2015 Feb;143(2):374-84. doi: 10.1093/toxsci/kfu235. Epub 2014 Nov 3.
91 Sorafenib induces preferential apoptotic killing of a drug- and radio-resistant Hep G2 cells through a mitochondria-dependent oxidative stress mechanism. Cancer Biol Ther. 2009 Oct;8(20):1904-13. doi: 10.4161/cbt.8.20.9436. Epub 2009 Oct 6.
92 Protective effect of sestrin2 against iron overload and ferroptosis-induced liver injury. Toxicol Appl Pharmacol. 2019 Sep 15;379:114665. doi: 10.1016/j.taap.2019.114665. Epub 2019 Jul 16.
93 Mechanisms of apoptosis induction by simultaneous inhibition of PI3K and FLT3-ITD in AML cells in the hypoxic bone marrow microenvironment. Cancer Lett. 2013 Feb 1;329(1):45-58. doi: 10.1016/j.canlet.2012.09.020. Epub 2012 Oct 2.
94 The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene. 2005 Oct 20;24(46):6861-9. doi: 10.1038/sj.onc.1208841.
95 Why are most phospholipidosis inducers also hERG blockers?. Arch Toxicol. 2017 Dec;91(12):3885-3895. doi: 10.1007/s00204-017-1995-9. Epub 2017 May 27.
96 The multikinase inhibitor sorafenib induces caspase-dependent apoptosis in PC-3 prostate cancer cells. Asian J Androl. 2010 Jul;12(4):527-34. doi: 10.1038/aja.2010.21. Epub 2010 May 17.
97 Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin. J Transl Med. 2005 Oct 28;3:39. doi: 10.1186/1479-5876-3-39.
98 GSK-3beta inhibition enhances sorafenib-induced apoptosis in melanoma cell lines. J Biol Chem. 2008 Jan 11;283(2):726-32. doi: 10.1074/jbc.M705343200. Epub 2007 Nov 8.
99 Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways. Mol Cancer Ther. 2006 Sep;5(9):2378-87. doi: 10.1158/1535-7163.MCT-06-0235.
100 Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation. Cancer Biol Ther. 2008 Oct;7(10):1648-62. doi: 10.4161/cbt.7.10.6623. Epub 2008 Oct 12.
101 TRIM62 silencing represses the proliferation and invasion and increases the chemosensitivity of hepatocellular carcinoma cells by affecting the NF-B pathway. Toxicol Appl Pharmacol. 2022 Jun 15;445:116035. doi: 10.1016/j.taap.2022.116035. Epub 2022 Apr 23.
102 Diospyros kaki leaves inhibit HGF/Met signaling-mediated EMT and stemness features in hepatocellular carcinoma. Food Chem Toxicol. 2020 Aug;142:111475. doi: 10.1016/j.fct.2020.111475. Epub 2020 Jun 6.
103 Comparative proteomic analysis of SLC13A5 knockdown reveals elevated ketogenesis and enhanced cellular toxic response to chemotherapeutic agents in HepG2 cells. Toxicol Appl Pharmacol. 2020 Sep 1;402:115117. doi: 10.1016/j.taap.2020.115117. Epub 2020 Jul 4.
104 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.